Healthcare -
Biotechnology - NASDAQ - US
$ 3.975
-2.09 %
$ 144 M
Market Cap
-0.99
P/E
1. INTRINSIC VALUE
Balance Sheet
Biomea Fusion, Inc.
| Current Assets | 179 M |
| Cash & Short-Term Investments | 177 M |
| Receivables | 0 |
| Other Current Assets | 2.32 M |
| Non-Current Assets | 20.7 M |
| Long-Term Investments | 0 |
| PP&E | 14.9 M |
| Other Non-Current Assets | 5.87 M |
| Current Liabilities | 22.9 M |
| Accounts Payable | 6.85 M |
| Short-Term Debt | 2.47 M |
| Other Current Liabilities | 13.5 M |
| Non-Current Liabilities | 7.83 M |
| Long-Term Debt | 7.83 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Biomea Fusion, Inc.
| Revenue | 0 |
| Cost Of Revenue | 4.2 M |
| Gross Profit | -4.2 M |
| Operating Expenses | 126 M |
| Operating Income | -126 M |
| Other Expenses | -8.88 M |
| Net Income | -117 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Biomea Fusion, Inc.
| Net Income | -117 M |
| Depreciation & Amortization | 1.52 M |
| Capital Expenditures | -3.37 M |
| Stock-Based Compensation | 14.1 M |
| Change in Working Capital | 2.33 M |
| Others | 2.46 M |
| Free Cash Flow | -100 M |
Wall Street Analysts Price Targets
Biomea Fusion, Inc.
Wall Street analysts predict an average 1-year price target for BMEA of $17.3 , with forecasts ranging from
a
low of
$5 to a high of $40 .
BMEA Lowest Price Target
Wall Street Target
5 USD
25.79%
BMEA Average Price Target
Wall Street Target
17.3 USD
334.86%
BMEA Highest Price Target
Wall Street Target
40 USD
906.29%
4. DIVIDEND
ANALYSIS
BMEA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Biomea Fusion, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
101 K USD 1
3-6 MONTHS
55.4 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
3 months ago
Sep 30, 2024
|
Bought
101 K USD
|
Hitchcock Michael J.M.
Director
|
+ 10000
|
10.06 USD |
|
7 months ago
Jun 11, 2024
|
Bought
55.4 K USD
|
Valle Franco
Chief Financial Officer
|
+ 12509
|
4.4257 USD |
|
1 year ago
May 31, 2023
|
Sell 2.54 M
USD
|
A2A Pharmaceuticals, Inc.
10 percent owner
|
- 75000
|
33.81 USD |
|
1 year ago
Jun 01, 2023
|
Sell 1.73 M
USD
|
A2A Pharmaceuticals, Inc.
10 percent owner
|
- 50000
|
34.5633 USD |
|
1 year ago
May 12, 2023
|
Sell 846 K
USD
|
A2A Pharmaceuticals, Inc.
10 percent owner
|
- 25000
|
33.84 USD |
|
1 year ago
May 08, 2023
|
Sell 3.4 M
USD
|
A2A Pharmaceuticals, Inc.
10 percent owner
|
- 100000
|
33.9931 USD |
|
1 year ago
May 09, 2023
|
Sell 5.18 M
USD
|
A2A Pharmaceuticals, Inc.
10 percent owner
|
- 150000
|
34.5048 USD |
|
1 year ago
Apr 20, 2023
|
Sell 5.82 M
USD
|
A2A Pharmaceuticals, Inc.
10 percent owner
|
- 200000
|
29.1188 USD |
|
1 year ago
Mar 31, 2023
|
Sell 6.25 M
USD
|
A2A Pharmaceuticals, Inc.
10 percent owner
|
- 200000
|
31.25 USD |
|
1 year ago
Mar 31, 2023
|
Sell 6.25 M
USD
|
A2A Pharmaceuticals, Inc.
10 percent owner
|
- 200000
|
31.25 USD |
|
1 year ago
Mar 30, 2023
|
Bought
12 M USD
|
Chen Bihua
director, 10 percent owner:
|
+ 400000
|
30 USD |
|
3 years ago
Apr 15, 2021
|
Bought
51 K USD
|
Erdtmann Rainer M
President and COO
|
+ 3000
|
17 USD |
|
3 years ago
Apr 15, 2021
|
Bought
40.8 K USD
|
Erdtmann Rainer M
President and COO
|
+ 2400
|
17 USD |
|
2 years ago
Nov 14, 2022
|
Bought
39.6 K USD
|
Hitchcock Michael J.M.
Director
|
+ 5000
|
7.93 USD |
|
2 years ago
Nov 11, 2022
|
Bought
31.3 K USD
|
Valle Franco
Chief Financial Officer
|
+ 4100
|
7.6307 USD |
|
2 years ago
Aug 16, 2022
|
Bought
426 K USD
|
A2A Pharmaceuticals, Inc.
director:
|
+ 30684
|
13.872 USD |
|
2 years ago
Jul 21, 2022
|
Sell 389 K
USD
|
A2A Pharmaceuticals, Inc.
director:
|
- 34658
|
11.21 USD |
|
2 years ago
Jun 24, 2022
|
Sell 408 K
USD
|
A2A Pharmaceuticals, Inc.
director:
|
- 34658
|
11.76 USD |
|
3 years ago
Jan 14, 2022
|
Bought
86.8 K USD
|
Valle Franco
Chief Financial Officer
|
+ 10000
|
8.6767 USD |
|
3 years ago
Sep 17, 2021
|
Bought
380 K USD
|
A2A Pharmaceuticals, Inc.
10 percent owner
|
+ 34658
|
10.96 USD |
|
3 years ago
Sep 17, 2021
|
Bought
380 K USD
|
Stergiopoulos Sotirios
Director
|
+ 34658
|
10.96 USD |
|
3 years ago
Aug 23, 2021
|
Bought
317 K USD
|
Erdtmann Rainer M
President & COO
|
+ 24000
|
13.203 USD |
|
3 years ago
Aug 23, 2021
|
Bought
317 K USD
|
Butler Thomas Andrew
CEO
|
+ 24000
|
13.203 USD |
|
3 years ago
Aug 18, 2021
|
Bought
151 K USD
|
Erdtmann Rainer M
President & COO
|
+ 14000
|
10.767 USD |
|
3 years ago
Aug 18, 2021
|
Bought
151 K USD
|
Erdtmann Rainer M
President & COO
|
+ 14000
|
10.767 USD |
|
3 years ago
Aug 17, 2021
|
Bought
151 K USD
|
Erdtmann Rainer M
President & COO
|
+ 14000
|
10.7905 USD |
|
3 years ago
Aug 17, 2021
|
Bought
151 K USD
|
Erdtmann Rainer M
President & COO
|
+ 14000
|
10.7905 USD |
|
3 years ago
Apr 15, 2021
|
Bought
3 M USD
|
Erdtmann Rainer M
President & COO
|
+ 176470
|
17 USD |
|
3 years ago
Apr 15, 2021
|
Bought
3 M USD
|
Erdtmann Rainer M
President & COO
|
+ 176470
|
17 USD |
|
3 years ago
Aug 18, 2021
|
Bought
151 K USD
|
Butler Thomas Andrew
CEO
|
+ 14000
|
10.767 USD |
|
3 years ago
Aug 17, 2021
|
Bought
151 K USD
|
Butler Thomas Andrew
CEO
|
+ 14000
|
10.7905 USD |
|
3 years ago
Apr 15, 2021
|
Bought
3 M USD
|
Butler Thomas Andrew
CEO
|
+ 176470
|
17 USD |
|
3 years ago
Apr 20, 2021
|
Bought
15.3 M USD
|
Chen Bihua
Director
|
+ 900000
|
17 USD |
7. News
Biomea's icovamenib meets HbA1c standards in T2D, says H.C. Wainwright
Biomea on Tuesday announced positive topline results from its Phase 2 COVALENT-111 trial evaluating icovamenib in patients with type 2 diabetes, with key takeaways including icovamenib displaying a statistically significant placebo-adjusted mean HbA1c reduction of 0.36% in the pre-specified per-protocol patient population and reduction of 0.42% after 12 weeks of treatments, H.C. Wainwright tells investors. Topline COVALENT-111 results validate the potential of icovamenib for long-term glycemic control with short-term treatment duration, the firm says. H.C. Wainwright made no change to its Buy rating or $40 price target.
https://thefly.com
- 1 month ago
Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?
On Tuesday, Biomea Fusion Inc. BMEA revealed topline results from the ongoing COVALENT-111 study of icovamenib in patients with type 2 diabetes (T2D).
benzinga.com
- 1 month ago
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced positive topline results from the ongoing COVALENT-111 study, evaluating the efficacy, safety and tolerability of icovamenib in patients with type 2 diabetes (T2D).
globenewswire.com
- 1 month ago
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Tuesday, December 17, 2024 at 8:00 am EST to present topline results from COVALENT-111, the company's Phase II trial of icovamenib in patients with type 2 diabetes.
globenewswire.com
- 1 month ago
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
REDWOOD CITY, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced the Company will present one oral presentation, one poster presentation, and host an oral symposium at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place in Los Angeles, California on December 12-14, 2024.
globenewswire.com
- 1 month ago
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
REDWOOD CITY, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced preliminary data from the ongoing Phase I COVALENT-103 study evaluating BMF-500, the company's investigational covalent FLT3 inhibitor developed using the proprietary FUSION™ System.
globenewswire.com
- 1 month ago
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Monday, December 9, 2024 at 4:30 pm EST to present data from COVALENT-103, the company's Phase I trial of BMF-500, an investigational covalent FLT3 inhibitor developed using the proprietary FUSION™ System, in adult patients with relapsed or refractory acute leukemia.
globenewswire.com
- 1 month ago
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that on December 2, 2024, the compensation committee of Biomea's board of directors granted one new employee non-qualified stock options to purchase an aggregate of 30,000 shares of the Company's common stock. The shares underlying the employee's stock options will vest 1/16 on a quarterly basis over four years, subject to the employee's continued employment with the Company on such vesting dates. The above-described award was made under Biomea's 2023 Inducement Equity Plan (the “Plan”).
globenewswire.com
- 1 month ago
The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Biomea Fusion, Inc. For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
accesswire.com
- 2 months ago
Biomea Fusion Inc Is Being Investigated For Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
accesswire.com
- 2 months ago
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
accesswire.com
- 2 months ago
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that on November 1, 2024, the compensation committee of Biomea's board of directors granted one new employee non-qualified stock options to purchase an aggregate of 6,500 shares of the Company's common stock. The shares underlying the employee's stock options will vest 1/16 on a quarterly basis over four years, subject to the employee's continued employment with the Company on such vesting dates. The above-described award was made under Biomea's 2023 Inducement Equity Plan (the “Plan”).
globenewswire.com
- 2 months ago
8. Profile
Summary
Biomea Fusion, Inc. BMEA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 144 M
Dividend Yield
0.00%
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Contact
900 Middlefield Road, Redwood City, CA, 94063
https://biomeafusion.com
IPO
Date
April 16, 2021
Employees
107
Officers
Mr. Franco Valle CPA
Chief Financial Officer & Principal Accounting Officer
Mr. Thomas Andrew Butler
Co-Founder, Chairman & Chief Executive Officer
Mr. Ramses M. Erdtmann
Co-Founder, President, Chief Operating Officer & Director
Dr. Juan Pablo Frias M.D.
Chief Medical Officer
Mr. Heow Tan
Chief Technology & Quality Officer
Ms. Naomi Cretcher
Chief People Officer
Dr. Thorsten Kirschberg Ph.D.
Executive Vice President of Chemistry
Dr. Stephan Morris M.D.
Chief Development Officer
Mr. Ravi Upasani
Executive Vice President of Intellectual Property
Caroline Perez- Dupont
Senior Vice President of Contracts